Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mitomycin Clear all
Withdrawn Phase 2 Interventional

Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene

NCT00386399
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Mitomycin-C
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 21, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional

Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites

NCT00265863
View directory record Official record
Conditions
Metastatic Cancer
Interventions
mitomycin C
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Not applicable Interventional Results available

InnFocus MicroShunt Versus Trabeculectomy Study

NCT01881425
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Glaucoma Surgery, InnFocus MicroShunt
Procedure · Device
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 21, 2026, 4:48 AM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety of UGN-101 in Recurrent Patients

NCT04006691
View directory record Official record
Conditions
Carcinoma, Transitional Cell Carcinoma, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
UGN-101 instillations
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Jacksonville, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT01011010
View directory record Official record
Conditions
Liver Cancer
Interventions
doxorubicin hydrochloride, mitomycin C, sorafenib tosylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 21, 2026, 4:48 AM EDT
Not yet recruiting Phase 2 Interventional

Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer

NCT06233877
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
G-GLIP plus Mitomycin C
Drug
Lead sponsor
Hirschfeld Oncology
Government
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 21, 2026, 4:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

NCT03386500
View directory record Official record
Conditions
Anal Cancer, Squamous Cell Carcinoma, Radiation Exposure
Interventions
BMX-001
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 4:48 AM EDT
Completed No phase listed Observational

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

NCT03604653
View directory record Official record
Conditions
Stomach Cancer, Colorectal Cancer, Appendiceal Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
HIPEC, Mitomycin c, CDDP 50, CDDP 75, Doxorubicin
Device · Drug
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 21, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Mitomycin C, Irinotecan, and Cetuximab

NCT00271011
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Mitomycin C, Cetuximab, Irinotecan.
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

Primary Tube Versus Trabeculectomy Study

NCT00666237
View directory record Official record
Conditions
Glaucoma
Interventions
Tube shunt surgery, Trabeculectomy, Mitomycin C
Procedure · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
12
States / cities
Sacramento, California • Gainesville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 21, 2026, 4:48 AM EDT
Recruiting Phase 1 Interventional

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

NCT04329494
View directory record Official record
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy, Irinotecan, Leucovorin, Mitomycin, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Duarte, California • Jacksonville, Florida • Greenlawn, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

NCT02852564
View directory record Official record
Conditions
Bladder Cancer
Interventions
Ethacrynic Acid
Drug
Lead sponsor
Eugene Lee, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

NCT02788201
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 21, 2026, 4:48 AM EDT
Active, not recruiting Phase 2 Interventional

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

NCT04858009
View directory record Official record
Conditions
Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8, Metastatic Malignant Neoplasm in the Peritoneum
Interventions
Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Nab-paclitaxel, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

NCT00956930
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres, Doxorubicin
Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

NCT03514888
View directory record Official record
Conditions
Invasive Bladder Cancer
Interventions
HIPEC
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 21, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

NCT04779554
View directory record Official record
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2
Drug
Lead sponsor
Prakash Pandalai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Lexington, Kentucky • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 21, 2026, 4:48 AM EDT
Active, not recruiting Early Phase 1 Interventional

Bladder Preservation or Cystectomy for MIBC

NCT07821177
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
Interventions
Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 4:48 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia

NCT00415077
View directory record Official record
Conditions
MODERATE AND HIGH MYOPIA
Interventions
PRK, MMC PRK, LASEK
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2010 · Synced Oct 21, 2026, 4:48 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131
View directory record Official record
Conditions
Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
Interventions
UGN-104
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Homewood, Alabama • Chandler, Arizona • Queen Creek, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 4:48 AM EDT
Terminated Phase 1 Interventional Results available

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

NCT01324141
View directory record Official record
Conditions
Anal Cancer
Interventions
Tempol, 5-Fluorouracil, Mitomycin-C, Radiation Therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ahmed Glaucoma Valve Surgery With Mitomycin-C

NCT02805257
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions
Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant
Drug · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 21, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

HIPEC for Peritoneal Carcinomatosis

NCT02040142
View directory record Official record
Conditions
Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma, Pseudomyxoma Peritonei, Gastric Cancer
Interventions
HIPEC, Mitomycin C
Procedure · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 21, 2026, 4:48 AM EDT
Terminated Not applicable Interventional Results available

Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer

NCT02716896
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
Radiation and chemoradiation, Radical cystectomy
Radiation · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 21, 2026, 4:48 AM EDT